Roivant Sciences (ROIV)
Develops immunology medicines and delivery technologies through focused Vant subsidiaries.
$38.35
After hours+0.13 (+0.34%)
At close$38.22(−1.97%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 77.60% | 560.56M shares | |
|---|---|---|---|
| 518 holders · as of Jun 30, 2026 | |||
| Insiders | 27.62% | 199.54M shares | |
| 12 holders · as of Sep 22, 2026 | |||
| Adds to | 105.22% | ||
722.32M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 105.22%; nothing is left for Other.
13F, as of Jun 30, 2026
518 holders · 560.56M shares · 99 new positions · 300 increased · 143 reduced · 46 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 81.02M | 11.22% | +3.04M | Aug 13, 2026 |
| BlackRock, Inc. | 48.24M | 6.68% | +3.98M | Aug 7, 2026 |
| Morgan Stanley | 42.59M | 5.90% | −9.24M | Aug 13, 2026 |
| QVT Financial LP | 23.72M | 3.28% | −1.44M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 22.12M | 3.06% | +1.44M | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 21.64M | 3.00% | +1.80M | Aug 13, 2026 |
| Goldman Sachs Group Inc | 18.56M | 2.57% | +7.44M | Aug 14, 2026 |
| State Street Corp | 17.80M | 2.46% | +1.61M | Aug 7, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 10.30% | 73.64M | 13G | Mar 6, 2026 |
| Morgan Stanley | 6.90% | 49.47M | 13G | May 12, 2026 |
| BlackRock, Inc. | 5.70% | 41.96M | Nov 8, 2024 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 15, 2026 | Meghan Fitzgeralddirector | Sale · 2 lots | 5,112 | $39.74 | 36,108 |
| Sep 15, 2026 | Melissa B. Epperlydirector | Sale · 2 lots | 4,938 | $39.74 | 9,900 |
| Sep 8, 2026 | Meghan Fitzgeralddirector | Sale | 20,000 | $39.90 | 42,963 |
| Aug 28, 2026 | Eric Venkerofficer: President & Immunovant CEO | Sale · 2 lots | 200,000 | $35.77 | 1,599,154 |
| Aug 21, 2026 | Mayukh Sukhatmedirector, officer: President & CIO | Sale | 144,756 | $36.48 | 18,630,739 |
| Aug 20, 2026 | Mayukh Sukhatmedirector, officer: President & CIO | Sale | 17,519 | $37.30 | 18,630,739 |
| Aug 19, 2026 | Mayukh Sukhatmedirector, officer: President & CIO | Sale | 172,899 | $37.17 | 18,630,739 |
| Aug 18, 2026 | Mayukh Sukhatmedirector, officer: President & CIO | Sale · 2 lots | 136,942 | $36.73 | 18,630,739 |
| Aug 17, 2026 | Mayukh Sukhatmedirector, officer: President & CIO | Sale | 284,707 | $36.25 | 18,630,739 |
| Aug 14, 2026 | Mayukh Sukhatmedirector, officer: President & CIO | Sale | 243,177 | $36.23 | 18,630,739 |
House and Senate disclosures
Not reported.